Q-omics provides the consensus-scored SEM1 profile across patient tissues and cancer cell-line models. SEM1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, SEM1 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SEM1 RNA expression shows 18,329 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, HNSC, and THYM as cancer lineages where SEM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEM1 survival associations across molecular data types. SEM1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (5) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEM1 RNA expression–survival associations across cancer types. High SEM1 expression shows unfavorable associations in UVM, KIRC, KICH, HNSC, LGG and KIRP. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for SEM1 RNA expression.
This table summarizes SEM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 3. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SEM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEM1 shows higher tumor expression in HNSC, KIRC, LUAD, COAD, BLCA and LIHC. The HNSC box plot shows higher SEM1 RNA expression in tumor versus normal tissue (log2 FC = +1.306, t-test p < 0.001).
This table shows molecular features associated with SEM1 in patient tissues and cancer cell lines. In patient samples, SEM1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and CNS.
